Parabilis Medicines
MA - CambridgeBiotechnology
Focus: Parabilis Medicines is a Cambridge-based biotech focused on cell-penetrating miniproteins for oncology, currently in early clinical development with a single Phase 1/2 program.
Profile data last refreshed 6h ago · AI intelligence enriched 2w ago
Total Funding
$305M
Open Jobs
13+3 this month
Stable — net +3 jobs in 30d
4 added, 1 removed. Backfill posture.
Should You Work at Parabilis Medicines?
AI assessmentParabilis is a high-risk, high-upside early-stage bet suitable only for biotech professionals comfortable with pre-revenue uncertainty in exchange for platform ownership and differentiated science.
Why Work Here
- Pioneering novel modality (cell-penetrating miniproteins) with differentiated IP in underdeveloped space — opportunity to build expertise in emerging technology
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
FOG-001
CancerClinical Trials (1)
NCT05919264FOG-001 in Locally Advanced or Metastatic Solid Tumors
Phase 1/2Help build intelligence for Parabilis Medicines
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.